Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Dec;131(12):E2880-E2886.
doi: 10.1002/lary.29675. Epub 2021 Jun 12.

Impact of Adjuvant Medical Therapies on Surgical Outcomes in Idiopathic Subglottic Stenosis

Matthew R Hoffman  1   2 , Ankita Patro  3 , Li-Ching Huang  4 , Sheau-Chiann Chen  4 , Lynn D Berry  4 , Alexander Gelbard  3 , David O Francis  2 ; North American Airway Collaborative
Collaborators, Affiliations
Clinical Trial

Impact of Adjuvant Medical Therapies on Surgical Outcomes in Idiopathic Subglottic Stenosis

Matthew R Hoffman et al. Laryngoscope. 2021 Dec.

Abstract

Objectives/hypothesis: Adjuvant medications including proton pump inhibitors (PPI), antibiotics (trimethoprim/sulfamethoxazole [TMP-SMX]), and inhaled corticosteroids (ICS) may be prescribed for patients with idiopathic subglottic stenosis (iSGS). We describe medication use with endoscopic dilation (ED) or endoscopic resection with medical treatment (ERMT) and evaluate impact on outcomes.

Study design: International, prospective, 3-year multicenter cohort study of 810 patients with untreated, newly diagnosed, or previously treated iSGS.

Methods: Post hoc secondary analysis of prospectively collected North American Airway Collaborative data on outcomes linked with adjuvant medication utilization. Primary outcome was time to recurrent operation, evaluated using Kaplan-Meier curves and Cox regression analysis. Secondary outcomes of change in peak expiratory flow (PEF) and clinical chronic obstructive pulmonary disease questionnaire (CCQ) score over 12 months were compared.

Results: Sixty-one of 129 patients undergoing ED received PPI (47%), and 10/143 patients undergoing ED received ICS (7%). TMP-SMX was used by 87/115 patients (76%) undergoing EMRT. PPI use in the ED group did not affect time to recurrence (hazard ratio [HR] = 1.00, 95% confidence interval [CI]: 0.53-1.88; P = .99) or 12-month change in PEF (L/min) (median [interquartile range], 12.0 [10.7-12.2] vs. 8.7 [-5.1 to 24.9]; P = .59), but was associated with 12-month change in CCQ (-0.05 [-0.97 to 0.75] vs. -0.50 [-1.60 to 0.20]; P = .04). ICS did not affect outcome measures. TMP-SMX use in ERMT did not affect time to recurrence (HR = 0.842, 95% CI: 0.2345-3.023; P = .79), PEF at 12 months (75 [68-89] vs. 81 [68-89]; P = .92), or 12-month change in CCQ (0.20 [-1.05 to 0.47] vs. -0.30 [-1.00 to 0.10]; P = .45).

Conclusion: There is no standard practice for prescribing adjuvant medications. These data do not support that adjuvant medications prolong time to recurrence or increase PEF. Patients with iSGS and gastroesophageal reflux disease may experience some symptom benefit with PPI.

Level of evidence: 3 Laryngoscope, 131:E2880-E2886, 2021.

Keywords: Idiopathic subglottic stenosis; adjuvant medical treatment; endoscopic dilation; endoscopic resection with medical therapy; inhaled corticosteroid; proton pump inhibitor; trimethoprim-sulfamethoxazole.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None.

Figures

Figure 1.
Figure 1.
Kaplan-Meier curve demonstrating recurrence of disease over time in patients undergoing endoscopic dilation with or without taking adjuvant proton pump inhibitor. There was no difference in time to recurrence.
Figure 2.
Figure 2.
Kaplan-Meier curve demonstrating recurrence of disease over time in patients undergoing endoscopic dilation with or without taking adjuvant inhaled corticosteroid. There was no difference in time to recurrence.
Figure 3.
Figure 3.
Kaplan-Meier curve demonstrating recurrence of disease over time in patients undergoing endoscopic resection with or without taking adjuvant trimethoprim/sulfamethoxazole. There was no difference in time to recurrence.
See this image and copyright information in PMC

References

    1. Gelbard A, Francis DO, Sandulache VC, et al. Causes and consequences of adult laryngotracheal stenosis. Laryngoscope 2015; 125(5):1137–43. - PMC - PubMed
    1. Mark EJ, Meng F, Kradin RL, Mathisen DJ, Matsubara O. Idiopathic tracheal stenosis: A clinicopathologic study of 63 cases and comparison of the pathology with chondromalacia. Am J Surg Pathol 2008; 32:1138–43. - PubMed
    1. Maldonado F, Loiselle A, DePew ZS, et al. Idiopathic subglottic stenosis: An evolving therapeutic algorithm. Laryngoscope 2014; 124:498–503. - PubMed
    1. Axtell AL, Mathisen DJ. Idiopathic subglottic stenosis: techniques and results. Ann Cardiothorac Surg 2018; 7(2):299–305. - PMC - PubMed
    1. Gelbard A, Donovan DT, Ongkasuwan J, et al. Disease homogeneity and treatment heterogeneity in idiopathic subglottic stenosis. Laryngoscope 2016; 126:1390–6. - PMC - PubMed

Publication types